Ucb S.A. (UCBJY)
UCBJY Stock Price Chart
Explore Ucb S.A. interactive price chart. Choose custom timeframes to analyze UCBJY price movements and trends.
UCBJY Company Profile
Discover essential business fundamentals and corporate details for Ucb S.A. (UCBJY) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Aug 2012
Employees
9.05K
Website
https://www.ucb.comCEO
Jean-Christophe Tellier
Description
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
UCBJY Financial Timeline
Browse a chronological timeline of Ucb S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Feb 2026
Earnings released on 31 Jul 2025
EPS came in at $2.02 surpassing the estimated $1.93 by +4.66%, while revenue for the quarter reached $3.99B , beating expectations by +6.85%.
Dividend declared on 16 Apr 2025
A dividend of $0.79 per share was announced, adjusted to $0.90. The dividend was paid on 14 May 2025.
Earnings released on 27 Feb 2025
EPS came in at $4.56 surpassing the estimated $1.35 by +237.78%, while revenue for the quarter reached $3.48B , beating expectations by +8.82%.
Earnings released on 25 Jul 2024
EPS came in at $1.15 surpassing the estimated $0.95 by +20.67%, while revenue for the quarter reached $3.00B , beating expectations by +3.85%.
Earnings released on 12 Jun 2024
EPS came in at $0.18 falling short of the estimated $0.73 by -75.92%, while revenue for the quarter reached $2.93B , beating expectations by +6.00%.
Dividend declared on 18 Apr 2024
A dividend of $0.73 per share was announced, adjusted to $0.78. The dividend was paid on 15 May 2024.
Earnings released on 30 Jun 2023
EPS came in at $1.74 surpassing the estimated $0.93 by +86.50%, while revenue for the quarter reached $2.82B , beating expectations by +0.51%.
Dividend declared on 11 Apr 2023
A dividend of $0.73 per share was announced, adjusted to $0.80. The dividend was paid on 18 May 2023.
Earnings released on 31 Dec 2022
EPS came in at $0.11 falling short of the estimated $0.40 by -73.63%, while revenue for the quarter reached $2.79B , beating expectations by +3.38%.
Earnings released on 30 Jun 2022
EPS came in at $2.14 surpassing the estimated $1.26 by +69.84%, while revenue for the quarter reached $3.06B , beating expectations by +9.81%.
Dividend declared on 23 Apr 2022
A dividend of $0.70 per share was announced, adjusted to $0.74. The dividend was paid on 18 May 2022.
Earnings released on 31 Dec 2021
EPS came in at $2.85 surpassing the estimated $1.49 by +91.28%, while revenue for the quarter reached $3.40B , beating expectations by +5.33%.
Earnings released on 30 Jun 2021
EPS came in at $3.48 surpassing the estimated $1.81 by +92.27%, while revenue for the quarter reached $3.30B , beating expectations by +3.71%.
Dividend declared on 30 Apr 2021
A dividend of $0.76 per share was announced, adjusted to $0.93. The dividend was paid on 19 May 2021.
Earnings released on 31 Dec 2020
EPS came in at $2.27 surpassing the estimated $1.23 by +84.55%, while revenue for the quarter reached $3.36B , beating expectations by +6.61%.
UCBJY Stock Performance
Access detailed UCBJY performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.